Continuous microcarrier-based cell culture in a benchtop microfluidic bioreactor

Archive ouverte

Abeille, Fabien | Mittler, Frédérique | Obeïd, Patricia | Huet, Maxime | Kermarrec, Frédérique | Dolega, Monika | Navarro, Fabrice P. | Pouteau, Patrick | Icard, Beatrice | Gidrol, Xavier | Agache, Vincent | Picollet-D’hahan, Nathalie

Edité par CCSD ; Royal Society of Chemistry -

International audience. Microfluidic bioreactors are expected to impact cell therapy and biopharmaceutical production due to their ability to control cellular microenvironments. This work presents a novel approach for continuous cell culture in a microfluidic system. Microcarriers (i.e., microbeads) are used as growth support for anchorage-dependent mammalian cells. This approach eases the manipulation of cells within the system and enables harmless extraction of cells. Moreover, the microbioreactor uses a perfusion function based on the biocompatible integration of a porous membrane to continuously feed the cells. The perfusion rate is optimized through simulations to provide a stable biochemical environment. Thermal management is also addressed to ensure a homogeneous bioreactor temperature. Eventually, incubator-free cell cultures of Drosophila S2 and PC3 cells are achieved over the course of a week using this bioreactor. In future applications, a more efficient alternative to harvesting cells from microcarriers is also anticipated as suggested by our positive results from the microcarrier digestion experiments.

Consulter en ligne

Suggestions

Du même auteur

Controlled 3D culture in Matrigel microbeads to analyze clonal acinar development

Archive ouverte | Dolega, Monika | CCSD

International audience

Distinct outcomes of CRL–Nedd8 pathway inhibition reveal cancer cell plasticity

Archive ouverte | Rulina, Anastasia | CCSD

International audience

Mechanical stress shapes the cancer cell response to neddylation inhibition

Archive ouverte | Mittler, Frédérique | CCSD

International audience. Abstract Background The inhibition of neddylation by the preclinical drug MLN4924 represents a new strategy to combat cancer. However, despite being effective against hematologic malignancies...

Chargement des enrichissements...